Ovid asks USP­TO to re­view Mar­i­nus' patent around treat­ment of se­ri­ous seizure con­di­tion

Ovid Ther­a­peu­tics is ramp­ing up its patent fight with Mar­i­nus Phar­ma­ceu­ti­cals.

The ri­val biotechs have been bat­tling for more than a year over patent claims cov­er­ing treat­ment meth­ods for epilep­tic dis­or­ders, in­clud­ing a dif­fi­cult-to-treat con­di­tion char­ac­ter­ized by long-last­ing seizures called sta­tus epilep­ti­cus (SE). On Tues­day, Ovid filed a new pe­ti­tion urg­ing the US Patent and Trade­mark Of­fice (USP­TO) to re­view Mar­i­nus’ Patent No. 11,110,100, which cov­ers meth­ods for ad­min­is­ter­ing Mar­i­nus’ Phase 3 can­di­date ganax­olone to treat SE.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER